|本期目录/Table of Contents|

[1]陈晓霞,李王平,马李杰,等.疏风解毒胶囊治疗老年急性上呼吸道感染的前瞻性研究[J].中华肺部疾病杂志,2020,(03):345-349.[doi:10.3877/cma.j.issn.1674-6902.2020.03.011]
　Qian Taotao,Shi Shunbin,Zhu Yong,et al.Expression difference and clinical significance of Th17 cell-related factors in patients with early stage and advanced stage of lung cancer[J].,2020,(03):345-349.[doi:10.3877/cma.j.issn.1674-6902.2020.03.011]
点击复制

疏风解毒胶囊治疗老年急性上呼吸道感染的前瞻性研究(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2020年03期
页码:
345-349
栏目:
论著
出版日期:
2020-06-20

文章信息/Info

Title:
Expression difference and clinical significance of Th17 cell-related factors in patients with early stage and advanced stage of lung cancer
作者:
陈晓霞1; 李王平1; 马李杰2; 金发光1; 潘 蕾1; 薛云丽3; 李翔宇4
710038 西安,空军(第四)军医大学唐都医院呼吸与危重症医学科1 610083 成都,西部战区总医院呼吸与危重症医学科2 100071 北京,北京远博康惠医药咨询有限公司3 236800 亳州,安徽济人药业有限公司4
Author(s):
Qian Taotao;  Shi Shunbin;  Zhu Yong;  Zhang Lin;  Wang Hailong.
Department of Thoracic Surgery, Ninth People's Hospital, Suzhou 215200, China
关键词:
疏风解毒胶囊;  老年人;  上呼吸道感染;  前瞻性研究
Keywords:
Bronchogenic carcinoma;  Early stage;  Advanced stage;  Th17 cell;  Related factors;  Expression difference
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2020.03.011
摘要:
目的 对比Th17细胞相关因子在不同分期非小细胞肺癌(NSCLC)患者中的表达差异,并分析临床意义,为肺癌免疫研究提供参考。方法 选择我院2016年2月至2019年2月收治的41例NSCLC患者为研究组,19例在我院接受常规体检的健康者作为对照组,全部受检者均接受Th17细胞及相关因子表达检测,包括白细胞介素-17(IL-17)、白细胞介素-21(IL-21),对比对照组与研究组Th17细胞相关因子表达情况,对比研究组不同性别、年龄Th17细胞相关因子表达; 根据研究组病理分期,对比不同病理分期NSCLC患者Th17细胞相关因子表达,经Pearson相关性分析Th17细胞相关因子与NSCLC病理分期的相关性。结果 研究组Th17细胞比例、IL-17水平、IL-21表达高于对照组,差异有统计学意义(P<0.05); 不同性别、不同年龄间NSCLC患者Th17细胞及其相关因子水平比较,差异均无统计学意义(P>0.05); 随着肿瘤分期增加,NSCLC患者外周血Th17细胞比例及IL-17、IL-21表达均呈升高趋势,各分期间两两比较差异均有统计学意义(P<0.05); Th17细胞比例、IL-17、IL-21表达与NSCLC患者肿瘤分期呈正相关(r=0.620、0.631、0.583,P均<0.001)。结论 NSCLC患者外周血中Th17细胞呈高表达,且随病情的进展不断升高,检测NSCLC患者外周血Th17细胞及其相关因子水平,对病情的判断及了解患者机体免疫功能有重要的临床意义。
Abstract:
Objective To compare the expression difference of Th17 cell-related factors in the patients with different stages of non-small cell lung cancer(NSCLC)in order to analyze its clinical significance and therefore provide references for the future study of lung cancer immunity. Methods A total of 41 patients with NSCLC in our hospital from February 2016 to February 2019 were included in the experimental group, and 19 healthy people through the routine physical examination were taken as the healthy control group. All the selected cases received Th17 cell-related factor detection, including interleukin-17(IL-17)and IL-21. The expression levels of Th17 cell-related factors between the healthy control group and the experimental group were compared, and the expression levels of Th17 cell-related factors of the patients with different genders and ages in the experimental group were compared respectively. The expression levels of Th17 cell-related factors in the patients with different pathological stages of NSCLC were compared, too. The correlation between the Th17 cell-related factors and the pathological stages of NSCLC was analyzed by Pearson correlation. Results The ratio of Th17 cells and the expression levels of IL-17 and IL-21 in the experimental group were higher than those of the healthy control group(P<0.05). There was no statistical difference in the Th17 cells and the related factors among the NSCLC patients with different genders and ages(P>0.05). With the increase of tumor stages, the ratio of Th17 cells in the peripheral blood and the expression levels of IL-17 and IL-21 in the patients with NSCLC showed an increasing trend, and the difference between the two groups was statistically significant(P<0.05). The ratio of Th17 cells and the expression levels of IL-17 and IL-21 had positive correlation with the tumor stages of the NSCLC patients(r=0.620, 0.631 and 0.583, respectively, P<0.001). Conclusion The expression levels of Th17 cells in the peripheral blood of the patients with NSCLC are higher compared with those of the healthy persons and they increase with the progress of the disease. Detecting the levels of Th17 cells and the related factors in the peripheral blood of the patients with NSCLC has an important clinical significance in the judgment of the disease and the understanding of the immune function.

参考文献/References:

1 张曦木, 张雪倩, 冯 聪, 等. 流行性感冒合并肺炎临床特征分析[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(1): 63-68.
2 徐艳玲, 张会红, 薛云丽, 等. 疏风解毒胶囊治疗急性上呼吸道感染(风热证)2031例Ⅳ期临床研究[J]. 中华中医药杂志, 2017(01): 356-360.
3 CFDA. 中药新药临床研究指导原则(试行)[M]. 北京: 中国医药科技出版社, 2002.
4 陈灏珠. 实用内科学[M]. 12. 北京:人民出版社, 2005.
5 Stolz D, Papakonstantinou E, Grize L, et al. Time-course of upper respiratory tract viral infection and COPD exacerbation[J]. Eur Respir J, 2019, 54(4).
6 Zwaans WA, Mallia P, van Winden ME, et al. The relevance of respiratory viral infections in the exacerbations of chronic obstructive pulmonary disease-a systematic review[J]. J Clin Virol, 2014, 61(2): 181-188.
7 马 莉, 黄 妍, 侯衍豹, 等. 疏风解毒胶囊对大鼠肺炎模型的抗炎机制研究[J]. 中草药, 2018, 49(19): 4591-4595.
8 姜小丽, 杨宝辉, 杨 婷, 等. 肺炎链球菌感染小鼠早期肺组织细胞因子变化研究[J]. 免疫学杂志, 2013, 29(6): 484-489.
9 张铁军, 朱 强, 许 浚, 等. 疏风解毒胶囊二次开发的系统研究[J]. 中草药, 2019, 15: 3517-3525.
10 李 迅. 疏风解毒胶囊佐治慢性阻塞性肺疾病急性加重期伴肺部感染的临床观察[J]. 中华中医药杂志, 2017, 32(1): 395-397.
11 Tao Z, Gao J, Zhang G, et al. Shufeng Jiedu Capsule protect against acute lung injury by suppressing the MAPK/ NF-κB pathway[J]. Biosci Trends, 2014, 8(1): 45-51.
12 薛明明, 高静琰, 陈东旭, 等. 高疏风解毒胶囊对D-氨基半乳糖/脂多糖诱导大鼠急性肝损伤保护作用[J]. 中草药, 2015, 46(9): 1348-1353.
13 何子龙, 方文娟, 张方博, 等. 疏风解毒胶囊肠吸收液对诱导巨噬细胞释放细胞因子的影响[J]. 中国现代中药, 2015, 17(4): 345-348.
14 王春兰, 吴学杰, 薛明明, 等. 疏风解毒胶囊联合抗生素治疗糖尿病合并肺部感染临床观察[J]. 上海中医药杂志, 2014, 48(11): 39-41, 48.
15 张连国, 李 艳. 疏风解毒胶囊对慢性阻塞性肺疾病急性加重期的疗效及营养指标影响[J]. 北京医学, 2015, 37(10): 974-976.
16 李 颖, 贾明月, 张 静, 等. 疏风解毒胶囊治疗社区获得性肺炎临床疗效及对抗生素使用时间的影响[J]. 中华中医药杂志, 2015, 30(6): 2239-2242.
17 何 龙, 赵 昕, 杨秀捷, 等. 疏风解毒胶囊预防急性肺损伤随机临床研究[J]. 中华中医药杂志, 2018, 32(1): 395-397.
18 赵建兰, 许东风, 李成勇. 疏风解毒胶囊治疗急性上呼吸道感染的疗效观察[J]. 中华中医药学刊, 2018, 32(5): 1222-1225.
19 李家飞, 陈长山, 蒋 琨. 疏风解毒胶囊治疗129例感冒后咳嗽患者的临床疗效分析及其对相关炎症因子的表达研究[J]. 临床肺科杂志, 2018, 23(7): 1346-1348.
20 田图磊, 荣 令, 瞿香坤, 等. 疏风解毒胶囊对慢性阻塞性肺疾病急性加重期炎性调节作用及疗效观察[J]. 中国中医急症, 2018(10): 1814-1816.
21 尹照萍, 孙 帅. 疏风解毒胶囊联合左氧氟沙星治疗慢性支气管炎急性加重期的临床研究[J]. 现代药物与临床, 2018(11): 2880-2883.
22 Shahan B, Barstow C, Mahowald M. Respiratory conditions: upper respiratory tract infections[J]. FP Essent, 2019, 486: 11-18.
23 钱雅琴, 吴飞虎, 朱 玲, 等. 疏风解毒胶囊的临床应用进展[J]. 时珍国医国药, 2018, 29(8): 1956-1958.
24 何 茹, 姜勇超, 钱 丹. 疏风解毒胶囊联合美敏伪麻溶液治疗小儿感染后咳嗽的临床研究[J]. 现代药物与临床, 2018, 33(12): 3208-3211.
25 徐艳玲, 薛云丽, 张会红, 等. 疏风解毒胶囊治疗急性上呼吸道感染风热证随机对照双盲试验[J]. 中医杂志, 2015, 56(8): 676-679.
26 李 颖, 王雪京. 疏风解毒胶囊治疗外感风热型急性鼻炎的临床疗效评价[J]. 中医药导报, 2015, 21(21): 49-51.
27 易新林, 马 欣, 邓可斌, 等. 疏风解毒胶囊治疗急性咽炎(风热证)临床观察[J]. 中国中医急症, 2017, 26(12): 2243-2244.
28 胡 蓉, 王丽华, 张珺珺, 等. 疏风解毒胶囊治疗急性咽炎风热证的临床观察[J]. 药物评价研究, 2014, 37(5): 460-462.
29 李 良, 宋瑞彪. 疏风解毒胶囊治疗慢性鼻窦炎不伴鼻息肉的临床观察[J]. 世界中西医结合杂志, 2015, 10(5): 688-702.
30 张金阳. 疏风解毒胶囊治疗慢性扁桃体炎急性发作疗效观察[J]. 中国中医急症, 2015, 24(12): 2230-2232.
31 冀庆军, 单荣英, 邓士敏, 等. 疏风解毒胶囊对OSAHS患者nCPAP治疗依从性的影响研究[J]. 世界中西医结合杂志, 2019, 14(5): 692-694, 699.
32 张 康, 王憭瑶, 李宣霖, 等. 疏风解毒胶囊治疗慢性阻塞性肺疾病急性加重的有效性与安全性Meta分析[J]. 中医研究, 2019, 32(6): 35-39.
33 刘 冉, 李宣霖, 王憭瑶, 等. 疏风解毒胶囊联合抗生素治疗社区获得性肺炎的Meta分析与GRADE评价[J]. 中医杂志, 2018(19): 1656-1660.

备注/Memo

备注/Memo:
通信作者: 李王平, Email: qxd25@163.com
更新日期/Last Update: 2020-06-20